Abu Dhabi, UAE; 9 January 2026: Ethmar International Holding (EIH), the UAE’s leading progressive investment holding, is partnering with FutureLife group to bring the internationally renowned Institut Marques assisted reproductive technology (ART) centre to Abu Dhabi. The new state-of-the-art facility will strengthen Abu Dhabi's position as a global hub for healthcare innovation and excellence.
Founded over a century ago, Institut Marques is a leader in assisted reproduction, recognized internationally for its groundbreaking advancements and success rates in fertility treatments. Its cutting-edge embryology laboratories, coupled with a multidisciplinary team of nearly 200 professionals, including gynecologists, embryologists and psychologists, have positioned Institut Marques among the highest-performing IVF providers globally, delivering success rates of up to 86%.
Currently operating clinics in Barcelona, Sabadell, Rome and Milan, Institut Marques will now bring its legacy of European clinical excellence and advanced technology to Abu Dhabi. The new center will integrate with Abu Dhabi’s advanced healthcare ecosystem, regulatory leadership and long-term national healthcare vision. Patients will have access to a comprehensive suite of fertility treatments and services.
With infertility affecting one in six adults globally, according to the World Health Organization (WHO), the introduction of Institut Marques to the UAE capital is a significant milestone in addressing this pressing global health challenge. The new center also aligns with EIH's commitment to supporting Abu Dhabi’s strategic goals, particularly in advancing medical and health tourism, and elevating local healthcare capabilities and patient experience.
EIH has mentioned that:
“Access to effective fertility remains a significant global challenge. By bringing Institut Marques to Abu Dhabi, EIH is underscoring its commitment to supporting the emirate’s ambition to become a regional and global healthcare hub. The strength and legacy of Institut Marques in Europe demonstrate its scalability, clinical governance and ability to deliver consistently across multiple markets.”